India's drug regulator has directed state drug authorities to strengthen surveillance of pharmaceutical supply chains after an Interpol alert flagged a counterfeit batch of semaglutide detected in Austria. The directive comes amid increasing demand for GLP-1 receptor agonists in India. The Central Drugs Standard Control Organisation (CDSCO) issued the nationwide directive after receiving a communication from the Central Bureau of Investigation (CBI) on July 7 regarding an Interpol intelligence alert originating from Austria.
According to the communication, Austrian authorities detected a counterfeit semaglutide product manufactured by Hilma Biocare, a European biotechnology company. Interpol identified the falsified product as batch number FJ3178 with an expiry date of February 2029 and requested that the alert be shared with relevant national agencies for monitoring. CDSCO has…
